Support LinksChrome Firefox Safari Edge View Versions © 2025 Advarra, Inc.

To search for a clinical trial (protocol), use any or all of the search fields: Select from drop down lists or type search criteria in any of the text fields. Browse by Physician or Drug, use the magnification icon …

Objectives The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who …

Objectives Primary Objective To compare overall survival in participants with newly diagnosed metastatic renal cell carcinoma who are randomized to receive immune checkpoint inhibitor-based …

Inclusion Criteria Pre-Registration Eligibility Criteria: Patients must have pathologically confirmed pancreatic adenocarcinoma.Received 4-6 months of induction chemotherapy with either …

Inclusion Criteria Eligibility Criteria: Patient must have a diagnosis of BRAFV600E/K-mutated metastatic melanoma.Patient must have had documented radiographic or clinical evidence of progressive …

SIP Version 14.0.0.010 Copyright © 2001-2020 Forte Research Systems, Inc. all rights reserved.

For additional information on all aspects of cancer, please contact the Huntsman Cancer Institute Information Service at the phone numbers listed below.

Exclusion Criteria Exclusion Criteria: Patients are excluded from the study if any of the following criteria apply: History of prior therapy with an anti-CD19 targeting agentActive acute or chronic GvHD …

Exclusion Criteria Exclusion Criteria: Patients are excluded from the study if any of the following criteria apply: Intraocular PCNSL with no brain lesionPatient who is intolerant of contrast-enhanced MRI due …